Ovagen
ET technology that delivers results
OVAGEN™ has high follicle stimulating hormone (FSH) activity coupled with extremely low luteinising hormone (LH) activity, which simplifies and increases the effectiveness of treatment protocols.
OVAGEN is different - it is manufactured from ovine pituitary glands. Physiologically sheep are much closer to cattle than pigs. Therefore, OVAGE's ovine base provides an effective platform for superovulating animals; particularly useful in treating animals that have not previously responded well to other superovulation programmes.
ICPbio's OVAGEN is extracted from ovine pituitaries sourced and processed in New Zealand, which is recognised by the EU as being free of BSE, Foot & Mouth and all List A (OIE) diseases, it is also free of other animal diseases of major significance.
OVAGEN was launched in 1985 and since then has been used to superovulate cattle, sheep, goats, and deer as well as many endangered species.
OVAGEN's low LH activity contributes to the simplicity of the treatment protocol.
IT MEANS:
- You can keep the level of FSH constant over the series of injections. As you don't have a descending dose, the FSH level is kept high over the last four injections at the time the follicles are being selected for ovulation.
- No interruption to existing ET programmes. OVAGEN™ can be used repeatedly on the same donor at regular intervals with no fall-off in response.
- Higher dose possible without adverse effect on the ovaries.
Include OVAGEN in your ET programme with total confidence in its efficacy, purity and consistency. Learn More
Registered pursuant to the ACVM Act 1997 No. A005291
Prescription Animal Remedy (P.A.R) Class l. For use only under the authority or prescription of a veterinarian.